Conclusion and Implications:
These data suggest that TGFβ1 and IL-18 may be the main
fibrogenic factors at different stages of liver fibrosis and that the
levels of inflammation-associated cytokines and signaling pathway
components decrease as the severity of hepatic fibrosis progresses.
Therefore, it may be better to apply anti-inflammatory drugs in the
early stage or use these drugs which facilitating more inflammatory
cells or cytokines into liver tissue at the end stage of hepatic
fibrosis.
Key words : liver fibrosis; cytokines; common bile duct ligation
(BDL); thioacetamide (TAA); signal pathway;